ReviewCancers2022
Anal Cancer in High-Risk Women: The Lost Tribe.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Outcomes reported in studies of anal high-grade squamous intraepithelial lesions treatments: systematic review.BJS open · 2026Pooled it
- Anal canal neoplasms in the modern era: integrating HPV biology, LAST terminology, and evolving molecular classification.Virchows Archiv : an international journal of pathology · 2026Review
- Risk stratification and anal cancer screening in immunocompetent women with genital HPV: Value of multicentric HSIL and performance of HPV-based screening.International journal of cancer · 2026Article
- Causative Human Papillomavirus (HPV) Genotypes of Anal Cancers in Australian Cisgender Women.Journal of medical virology · 2026Article
- Women with HPV-Driven Anal and Genital Disease: Investigating the Patient Cohort in England.Cancers · 2025Article
- MRI-based radiomics nomogram to predict complete response to definitive chemoradiation in patients with anal cancer.The British journal of radiology · 2025Article
- Article
- Radiomics to predict tumor response to combination chemoradiotherapy in squamous cell carcinoma of the anal canal: a preliminary investigation.European radiology experimental · 2025Article
- Challenges in the implementation of a high-resolution anoscopy clinic for people with HIV in an oncologic center in Mexico City.AIDS research and therapy · 2025Article
- Anogenital HPV-Related Cancers in Women: Investigating Trends and Sociodemographic Risk Factors.Cancers · 2024Article
- Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021).Human vaccines & immunotherapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In developed countries the incidence of anal squamous cell carcinoma (SCC) has been rising; especially in women over the age of 60 years who present with more advanced disease stage than men. Historically, anal SCC screening has focused on people living with Human Immunodeficiency Virus (HIV) (PLWH) who are considered to be at the highest risk of anal SCC, and its precancerous lesion, anal squamous intraepithelial lesion (SIL). Despite this, women with vulval high-grade squamous epithelial lesions (HSIL) and SCCs have been shown to be as affected by anal HSIL and SCC as some PLWH. Nevertheless, there are no guidelines for the management of anal HSIL in this patient group. The ANCHOR trial demonstrated that treating anal HSIL significantly reduces the risk of anal SCC in PLWH, there is therefore an unmet requirement to clarify whether the screening and treatment of HSIL in women with a prior genital HSIL is also beneficial. This review presents the current evidence supporting the screening, treatment, and surveillance of anal HSIL in high-risk women with a previous history of genital HSIL and/or SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.